Ellington Management Group’s Pacira BioSciences PCRX Stock Holding History

Ellington Management Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,400	Closed	-$700K	–	702
2019 Q3	$700K	Buy	+18,400	New	+$734K	0.13%	171
2015 Q3	–	Sell	-4,095	Closed	-$290K	–	850
2015 Q2	$290K	Sell	4,095 -19,005	-82%	-$1.5M	0.07%	442
2015 Q1	$2.05M	Buy	23,100 +16,000	+225%	+$1.62M	0.42%	37
2014 Q4	$629K	Buy	7,100 +4,800	+209%	+$454K	0.21%	126
2014 Q3	$223K	Buy	+2,300	New	+$224K	0.15%	218
2014 Q2	–	Sell	-31,400	Closed	-$2.2M	–	613
2014 Q1	$2.2M	Buy	+31,400	New	+$2.14M	0.64%	6

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ellington Management Group's PCRX Position: Q4 2019 in Review

Ellington Management Group sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 18,400 shares — an estimated $700K sold.

Ellington Management Group first reported a position in PCRX in Q1 2014 and held it in 6 quarters. The position peaked at $2.2M in Q1 2014. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

Ellington Management Group reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
Ellington Management Group sold 18,400 Pacira BioSciences shares in Q4 2019, an estimated $700K.
Ellington Management Group first reported a position in Pacira BioSciences in Q1 2014 and held it in 6 quarters.
Ellington Management Group's Pacira BioSciences position peaked at $2.2M in Q1 2014.
231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Ellington Management Group's 13F filing for Q4 2019, filed 14 Feb 2020.